Skip to main navigation Skip to search Skip to main content

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TCC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects w

Project: Research

Project Details

StatusFinished
Effective start/end date04/6/16 → 04/5/19

Funding

  • Gilead Sciences Incorporated: $57,832.00